National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996-2010 in the United States: A cross-sectional study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Oramasionwu, Christine U ^a   Toliver, Joshua C ^a   Johnson, Terence L ^a   Moore, Heather N ^a   Frei, Christopher R ^b,c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Coinfection; HCV; Health care utilization; HIV; Hospitalization

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BRONCHOSCOPY; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNICITY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEPATITIS C; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ICD-9-CM; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; PATIENT CARE; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES; EPIDEMIOLOGY; HEPATITIS C, CHRONIC; HIV INFECTIONS; HOSPITAL PATIENT; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INPATIENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; UNITED STATES;

EID: 84964315566     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-536     Document Type: Article

References (18)

1. Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA: The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 2011, 18(7):506-512.
2. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996, 335(15):1091-1098.
3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339(21):1485-1492.
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT: Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351(5):438-450.
5. Ananthakrishnan AN, McGinley EL, Fangman J, Saeian K: Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. J Viral Hepat 2010, 17(10):720-729.
6. Gebo KA, Diener-West M, Moore RD: Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003, 34(2):165-173.
7. Backus LI, Boothroyd D, Deyton LR: HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS 2005, 19(Suppl 3):S13-S19.
8. Myers RP, Liu M, Shaheen AA: The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008, 22(4):381-387.
9. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156(4):271-278.
10. Sie L, Gatto NM, Bancroft E: Hospitalizations due to hepatitis C in Los Angeles County, 2007-2009: case characteristics and factors associated with mortality. J Viral Hepat 2013, 20(9):628-637.
11. Workowski KA, Berman S, Centers for Disease C, Prevention: Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59(RR-12):1-110.
12. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA: Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 2009, 48(6):816-821.
13. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 115F [http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf]
14. Strader DB: Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis 2005, 41(Suppl 1):S7-S13.
15. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364(25):2405-2416.
16. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206.
17. FDA Approval: Olysio (simeprevir) for the treatment of chronic hepatitis C in combination antiviral treatment. [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376449.htm]
18. FDA Approval: Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm]